SCHEMBL16466950

SCHEMBL16466950

COc1ccccc1CN1CCOC(O)C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ RAB9A P51151 1/20 0.47
▸ KMT2A Q03164 3/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ TP53 P04637 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ BRD4 O60885 1/20 0.44
▸ POLB P06746 2/20 0.43
▸ HDAC3 O15379 1/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HDAC7 Q8WUI4 1/20 0.43
▸ HDAC2 Q92769 1/20 0.43
▸ HDAC10 Q969S8 1/20 0.43
▸ HDAC11 Q96DB2 1/20 0.43
▸ HDAC8 Q9BY41 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ HDAC9 Q9UKV0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16466985 0.84 ALDH1A1 (0.48) KMT2AMEN1SMN1; SMN2POLBHDAC3
SCHEMBL16467037 0.80 CYP1A2 (0.50) TP53CYP2D6POLBALDH1A1
SCHEMBL16466706 0.77 SIRT2 (0.47) KMT2AMEN1KDM4EALDH1A1
SCHEMBL16467013 0.77 SIRT2 (0.47) SMN1; SMN2BRD4ALDH1A1
SCHEMBL12208454 0.76 TACR1 (0.51) KMT2AMEN1CYP2D6POLBHDAC1
SCHEMBL28120391 0.76 TACR1 (0.51) KMT2AMEN1CYP2D6POLBHDAC1
SCHEMBL16466966 0.76 GAA (0.49) SMN1; SMN2ALDH1A1
SCHEMBL16466757 0.76 SIRT2 (0.48) KMT2AMEN1POLBKDM4EALDH1A1
SCHEMBL8565231 0.75 MEN1 (0.52) USP2HSD17B10RAB9AKMT2AMEN1
SCHEMBL8565227 0.75 MEN1 (0.52) USP2HSD17B10RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2837624-B1 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF ZHEJIANG HISUN PHARM CO LTD (CN) 2018-06-27 — — EP disclosed
US-9676736-B2 4-substituent-2-hydroxylmorpholine-3-one and preparation method thereof ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2017-06-13 — — US disclosed
US-20150087828-A1 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2015-03-26 — — US disclosed
EP-2837624-A1 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) 2015-02-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087828-A1 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF OPRK1, HTR3C, HTR3A USP2 2249/4885HSD17B10 3160/4885RAB9A 3518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback